To have your company profiled contact us at info@vegashotstocks.com
Advaxis, Inc. (ADSX)
Advaxis, Inc. (OTCBB ADXS): Advaxis, Inc. is a biotechnology company that uses a modified infectious microorganism to activate the immune system to treat cancer, infectious disease or allergic syndromes. Based upon over a 10 years of innovative work done by Yvonne Paterson, Ph.D., Professor of Microbiology at the University of Pennsylvania, it has been found that the unique microbe Listeria monocytogenes is capable of stimulating numerous aspects of the immune system simultaneously; coordinating innate, humoral (antibody), and cellular adaptive immune responses in an extremely effective response to existing cancers and other diseases. Unlike other therapeutic approaches, in pre-clinical research Advaxis’ Listeria technology has been able to consistently demonstrate complete therapeutic responses resulting in complete tumor regression.
Etrade Financial ( ETFC )
The value behind E*TRADE FINANCIAL's name lies in its tireless effort to challenge the old ways of doing business. We succeed in delivering a diversified and integrated portfolio of innovative, customer-focused brokerage and banking products and services by remaining true to our operating ideals and well-proven formula-regularly asking, can this be done better? By applying this level of discipline to our Retail, Corporate and Institutional businesses, we are able to deliver long-term value to our customers and to our shareholders.
Mission Statement:
To create long term shareholder value through superior financial performance driven by the delivery of a diversified range of innovative, customer-focused financial products and services and supported by an operating culture based on the highest levels of teamwork, efficiency and integrity.
ARIAD Pharmaceuticals, Inc . ( ARIA )
ARIAD Pharmaceuticals, Inc. engages in the discovery and development of medicines to treat cancers by regulating cell signaling with small molecules in the United States. The company's lead cancer product candidate, AP23573, is an mTOR inhibitor for the treatment of solid tumors, including sarcomas, hormone refractory prostate cancer, endometrial cancer, brain cancer, and leukemias and lymphomas. It studies AP23573 in multiple clinical trials in the U.S. and Europe, and is conducting Phase II clinical trials as a single agent in patients with solid tumors, including sarcomas, hormone refractory prostate cancer, endometrial cancer, brain cancer, and leukemias and lymphomas.